Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Chuvin

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Science Advances|February 15, 2023
TCR-engineered T cell therapy in solid tumors: State of the art and perspectivesEstelle Baulu, Célia Gardet, Nicolas Chuvin, et al.
Cellular & Molecular Immunology|March 5, 2024
Development of NK cell-based cancer immunotherapies through receptor engineeringAudrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, et al.
Bulletin Du Cancer|December 18, 2021
[T cell-based immunotherapies in solid tumors]Estelle Baulu, Aurore Dougé, Nicolas Chuvin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2022
Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapyMarion Mallet, Rasha E Boulos, Vincent Alcazer, et al.
The Journal of Cell Biology|May 14, 2014
Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-βLindsay B Alcaraz, Jean-Yves Exposito, Nicolas Chuvin, et al.
Science Advances|January 26, 2022
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapyPaola Bonaventura, Vincent Alcazer, Virginie Mutez, et al.
Genesis (New York, N.Y. : 2000)|March 20, 2020
Generation of an Fsp1 (fibroblast-specific protein 1)-Flpo transgenic mouse strainVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
Scientific Reports|March 5, 2020
Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblastsVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
American Journal of Hematology|June 27, 2022
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapyVincent Alcazer, Paola Bonaventura, Laurie Tonon, et al.
Cancer Research|August 19, 2015
TIF1γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal StabilityRoxane M Pommier, Johann Gout, David F Vincent, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Science Advances|February 15, 2023
TCR-engineered T cell therapy in solid tumors: State of the art and perspectivesEstelle Baulu, Célia Gardet, Nicolas Chuvin, et al.
Cellular & Molecular Immunology|March 5, 2024
Development of NK cell-based cancer immunotherapies through receptor engineeringAudrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, et al.
Bulletin Du Cancer|December 18, 2021
[T cell-based immunotherapies in solid tumors]Estelle Baulu, Aurore Dougé, Nicolas Chuvin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2022
Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapyMarion Mallet, Rasha E Boulos, Vincent Alcazer, et al.
The Journal of Cell Biology|May 14, 2014
Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-βLindsay B Alcaraz, Jean-Yves Exposito, Nicolas Chuvin, et al.
Science Advances|January 26, 2022
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapyPaola Bonaventura, Vincent Alcazer, Virginie Mutez, et al.
Genesis (New York, N.Y. : 2000)|March 20, 2020
Generation of an Fsp1 (fibroblast-specific protein 1)-Flpo transgenic mouse strainVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
Scientific Reports|March 5, 2020
Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblastsVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
American Journal of Hematology|June 27, 2022
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapyVincent Alcazer, Paola Bonaventura, Laurie Tonon, et al.
Cancer Research|August 19, 2015
TIF1γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal StabilityRoxane M Pommier, Johann Gout, David F Vincent, et al.
Pageof 2